By Nancy Glick, NCL Director of Food and Nutrition Policy
The American frontier between 1865 and 1890 is etched into the cultural consciousness as the “Wild West”—a vast, untamed expanse defined by a lack of government oversight, crumbling infrastructure, and the absence of reliable law enforcement. It was an era that flourished during the gold rush, a period when outlaws and vigilantes operated with near impunity.
Today, a modern-day digital Wild West has emerged, fueled not by gold nuggets in riverbeds, but by the skyrocketing demand for weight-loss miracle drugs. This current landscape, however, is far more lethal than its predecessor. Instead of dusty shootouts, this digital frontier puts public health in the crosshairs by facilitating an unregulated online marketplace for unapproved GLP-1 (glucagon-like peptide-1) receptor agonists and experimental peptides. These substances, often manufactured in shadow facilities, are causing severe physical harm, permanent injury, and, in increasingly documented cases, death.
The Genesis of the Crisis: A Compounding Conundrum
The origins of this crisis can be traced to 2022, when global shortages of blockbuster medications like semaglutide and tirzepatide created a supply-demand vacuum. Under existing FDA regulations, compounding pharmacies are permitted to create "non-identical" versions of drugs when the original branded versions are in short supply.
Seizing upon this loophole, a flood of compounding pharmacies—many lacking the rigorous sterility protocols of pharmaceutical giants—began producing monthly injectable versions of these drugs. Telehealth companies and opportunistic online retailers marketed these products aggressively, claiming they offered the same safety and efficacy as FDA-approved medications at a fraction of the cost. By 2024, nearly one in three consumers seeking GLP-1 weight-loss support had turned to these compounded alternatives.
The National Consumers League (NCL) sounded the alarm early, issuing a national alert based on FDA warnings: compounded GLP-1s are not tested, reviewed, or approved by the FDA. They lack the stringent oversight required to ensure consistent dosing, leaving patients vulnerable to potency variations and, more terrifyingly, exposure to toxic contaminants.
Chronology of a Regulatory Failure
- 2022: Shortages of branded semaglutide and tirzepatide trigger FDA "shortage" status, allowing compounding pharmacies to enter the market.
- 2024: NCL issues its first national alert as one-third of consumers report using compounded GLP-1s.
- 2025: As official supply chains normalize, the FDA sets a May 2025 deadline for compounders to stop selling mass-produced versions.
- Late 2025 – Early 2026: Compounders pivot to "personalized" microdoses and "vitamin-boosted" formulations to bypass the ban, leading to a surge in reported adverse events.
- April 2026: The FDA formally proposes excluding semaglutide, tirzepatide, and liraglutide from the "503B bulks list," signaling an end to the era of mass-market compounding.
- June 2026: Global health alerts skyrocket as black-market retatrutide—an experimental, unapproved drug—is linked to organ failure in Australia and the United States.
From Gray Markets to the Black Market
As the FDA tightened the noose on compounded pharmacies, the "Wild West" metastasized into a true black market. Regulatory loopholes that once allowed for the mass marketing of "compounded" drugs are now being exploited by gray-market vendors and illicit criminal enterprises.
These entities are selling raw active pharmaceutical ingredients (APIs) and "research-grade" experimental peptides—substances banned in Canada, Australia, the European Union, and by the World Anti-Doping Agency—directly to consumers. Among the most dangerous of these is retatrutide. Currently only in clinical trials, retatrutide is not approved for human use anywhere in the world. Yet, counterfeit, powdered versions sourced from unregulated overseas manufacturers—primarily in China—are flooding the internet with DIY dosing instructions.
Because these black-market products are produced without any oversight, there is no guarantee of purity. Investigations have revealed that these "research chemicals" often contain substituted substances, heavy metal impurities, or entirely different active compounds. The consequences are immediate and catastrophic.
Supporting Data: A Public Health Epidemic
The human cost of this unregulated trade is quantifiable and grim. CBS News reported that calls to America’s Poison Centers regarding retatrutide surged to an average of 95 cases per month in early 2026—a staggering 265% increase from late 2025.
The international community is witnessing similar horrors. In June 2026, health authorities in Australia issued an urgent warning after users of black-market retatrutide suffered from acute liver failure, major kidney injuries, and life-threatening cardiac arrhythmias.
The reliance on social media for medical advice has exacerbated the danger. A May 2026 study by the telehealth company Sunlight found that a terrifying 45% of peptide users who purchased their compounds via social media platforms required emergency room treatment due to severe adverse reactions. The digital landscape—TikTok, Instagram, Telegram, and Discord—has become the primary distribution hub for these substances, with influencers often acting as the "pharmacists" of this deadly trade.
Official Responses and Industry Complicity
The pharmaceutical industry, led by companies like Eli Lilly and Company, has sounded the alarm. Lilly has reported more than 14,000 instances of illicit marketing for retatrutide across social media, e-commerce sites, and internet service providers. Yet, the platforms hosting this content have been slow to act.
A November 2025 Reuters investigation exposed that Meta earned approximately $7 billion in annualized revenue from "higher-risk" scam advertisements, including AI-generated misleading marketing for weight-loss products. Despite violating their own internal policies regarding fraudulent content, these platforms have allowed a deluge of illicit activity to persist.
A study published in JAMA found that by May 2026, there were over 130,000 Instagram posts and 230 million TikTok views promoting the use of illicit injectable peptides. These platforms are not merely passive hosts; they are the primary conduits through which vulnerable consumers are funneled toward encrypted messaging apps, where the final, illegal transactions take place.
Implications: The Path Forward
The situation has reached a breaking point. We are witnessing a public health crisis that transcends borders, characterized by a torn esophagus in an Australian patient—linked to fake retatrutide—and thousands of similar, albeit less publicized, tragedies globally.
Warnings, while necessary, are insufficient. The NCL and the broader patient safety community are now calling for a fundamental shift in how social media platforms interact with public health. The digital Wild West must be brought to heel through the following actions:
- Platform Accountability: Social media giants must move beyond lip service. This requires the deployment of proactive AI detection specifically tuned to identify coded language and "dog-whistle" terminology used to promote illicit peptides.
- Cross-Agency Coordination: The FDA, Federal Trade Commission, customs agencies, and state attorneys general must harmonize their efforts to track and shut down the upstream suppliers—the manufacturers of these toxic powders—before they reach the consumer.
- Blocking and Banning: Platforms must move toward a policy of permanent, zero-tolerance bans for sellers who attempt to redirect users to encrypted apps for the purchase of unapproved pharmaceuticals.
- Public Literacy: We must educate consumers on the extreme risks of purchasing "research-grade" substances. If a drug is not prescribed by a licensed physician and dispensed by a verified, legal pharmacy, it is not medicine—it is a poison.
The era of the digital Wild West must end. The "gold" being chased by these illicit vendors is bought with the lives and health of unsuspecting patients. It is time for regulators and tech giants to stop facilitating this market and start dismantling it, before the next wave of victims is even further beyond our reach.
